Expert Review of Cardiovascular Therapy最新文献

A scoping review of factors associated with the prescribing choice of direct oral anticoagulant drugs. 与直接口服抗凝药物处方选择相关因素的范围审查。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-25 DOI: 10.1080/14779072.2025.2536043

Hanan Abunimeh, Solafa NoorSaeed, Rahaf Alkhlaifat, Amanj Kurdi, Tanja Mueller

{"title":"A scoping review of factors associated with the prescribing choice of direct oral anticoagulant drugs.","authors":"Hanan Abunimeh, Solafa NoorSaeed, Rahaf Alkhlaifat, Amanj Kurdi, Tanja Mueller","doi":"10.1080/14779072.2025.2536043","DOIUrl":"10.1080/14779072.2025.2536043","url":null,"abstract":"Introduction: With the substantial increase in direct oral anticoagulant (DOAC) usage, prescribers face complex decisions regarding the appropriate agent selection. This scoping review aimed to identify factors influencing oral anticoagulant choice in clinical practice over time.Methods: Four databases (Medline, Embase, Scopus, Web of Science) were searched for quantitative observational studies on patients prescribed DOACs for any indication, focusing on factors affecting OAC choice. Studies published from January 2010 to March 2023 were included.Results: Of the 4659 identified studies, 60 met selection criteria. Most (96%) examined the choice between DOACs and vitamin K antagonists (VKA); while (15%) evaluated factors affecting choice among DOACs. Age and gender were included in 77% and 70% of studies, respectively. Renal impairment (58%), heart failure (48%), previous stroke (43%), and thromboembolic risk (43%) were also commonly assessed. Older age had a significant negative association with DOAC prescribing in (50%) of the studies; renal impairment reduced DOAC initiation, favoring warfarin in (94%).Conclusions: Several significant key factors were identified as being associated with OAC choice, including demographic factors such as age, and clinical factors such as kidney function, prior stroke, and other comorbidities. Significant factors in the choice among DOACs were advanced age, and renal impairment.Registration: This systematic review was registered as a PURE protocol (https://pureportal.strath.ac.uk/en/projects/factors-associated-with-the-prescribing-of-direct-acting-oral-ant).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-19"},"PeriodicalIF":1.8,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How could ultraslow low-dose thrombolytic infusion regimes affect high thrombosis resolution rates in prosthetic valve thrombosis? 超低低剂量溶栓输注方案如何影响人工瓣膜血栓形成的高血栓溶解率？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-23 DOI: 10.1080/14779072.2025.2536050

Sabahattin Gunduz, Mehmet Ozkan

{"title":"How could ultraslow low-dose thrombolytic infusion regimes affect high thrombosis resolution rates in prosthetic valve thrombosis?","authors":"Sabahattin Gunduz, Mehmet Ozkan","doi":"10.1080/14779072.2025.2536050","DOIUrl":"10.1080/14779072.2025.2536050","url":null,"abstract":"Introduction: Prosthetic valve thrombosis (PVT) is a life-threatening complication of mechanical heart valve replacement. Management has evolved over decades, from urgent surgical intervention to low dose ultraslow thrombolytic therapy.Areas covered: This review provides a historical to present-day analysis of thrombolytic strategies in PVT, comparing accelerated dosing with slower infusion protocols. We synthesize clinical evidence and elucidate mechanistic insights into how infusion rate and dosage influence clot resolution and safety. We searched the PubMed database from inception to May 2025 using combinations of appropriate keywords.Expert opinion: The development of lower dose, slower infusion protocols, notably using Alteplase without bolus, has dramatically improved outcomes. Clinical trials show comparable or superior thrombosis resolution rates with ultraslow infusion versus rapid infusion or surgery, but with markedly reduced complication rates. Mechanistically, ultraslow infusion may help to localize fibrinolysis to the thrombus site, minimizing systemic fibrinogen depletion and hemorrhagic risk. Ultraslow (25 hours) low-dose (25 mg) thrombolysis with Alteplase is a safe and effective first-line therapy for PVT patients, achieving high success in clot resolution while limiting bleeding and embolic complications. Ongoing evidence and mechanistic rationale suggest that, in the absence of contraindications, this strategy can often be preferable to traditional rapid high-dose thrombolysis or emergency surgery.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144667499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prevention of unfavorable fibrin clots and thrombo-embolic manifestations in patients with cardiovascular disease. 心血管疾病患者不良纤维蛋白凝块和血栓栓塞表现的预防

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-21 DOI: 10.1080/14779072.2025.2536048

Elżbieta Paszek, Anetta Undas

{"title":"Prevention of unfavorable fibrin clots and thrombo-embolic manifestations in patients with cardiovascular disease.","authors":"Elżbieta Paszek, Anetta Undas","doi":"10.1080/14779072.2025.2536048","DOIUrl":"10.1080/14779072.2025.2536048","url":null,"abstract":"Introduction: Compelling evidence shows that unfavorably altered (prothrombotic) fibrin clot properties such as more compact and poorly lysable fibrin networks contribute to thrombo-embolic events in cardiovascular disease.Areas covered: Following a literature search in Medline, Embase, TRIP, and the Cochrane Database of Systematic Reviews, this review summarizes the current evidence on therapeutic strategies, that are currently used or tested in cardiovascular disease including coronary artery disease, peripheral artery disease, atrial fibrillation, heart failure, and their thrombotic manifestations, in particular myocardial infarction and ischemic stroke, in the context of altered plasma fibrin clot characteristics.Expert opinion: Anticoagulants (heparins, vitamin K antagonists, and direct oral anticoagulants), aspirin, and statins favorably modify fibrin clot characteristics, which might contribute to their efficacy in various clinical settings. Encouraging results suggest that novel treatments not yet approved in cardiovascular disease, including factor XI inhibitors and lipoprotein (a) reducing agents, might be beneficial, in part through improved fibrin clot phenotype, which gives hope for reducing the residual risk of thromboembolism in cardiovascular disease, which persists despite the recommended management.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-16"},"PeriodicalIF":1.8,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658703","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of SGLT2 inhibitors on functional outcomes in heart failure patients according to the aetiology. 根据病因，SGLT2抑制剂对心力衰竭患者功能结局的影响

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-20 DOI: 10.1080/14779072.2025.2534712

Emanuele Coppo, Alberto Giráldez Valpuesta, Juan José Serrano Silva, Jaime Fernández Rebollo, Eva González Caballero, Sergio Gamaza Chulián

{"title":"Impact of SGLT2 inhibitors on functional outcomes in heart failure patients according to the aetiology.","authors":"Emanuele Coppo, Alberto Giráldez Valpuesta, Juan José Serrano Silva, Jaime Fernández Rebollo, Eva González Caballero, Sergio Gamaza Chulián","doi":"10.1080/14779072.2025.2534712","DOIUrl":"10.1080/14779072.2025.2534712","url":null,"abstract":"Background: Exercise intolerance is a significant symptom of heart failure with reduced ejection fraction (HFrEF) and is associated with poor outcomes. While sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits, their impact on functional capacity remains debated. This study aimed to assess the effects of SGLT2i on exercise capacity and quality of life in patients with ischemic and non-ischemic HFrEF.Research design and methods: Patients with a recent diagnosis of HFrEF and stable clinical status, referred to a heart failure unit, were prospectively enrolled. Exercise capacity was evaluated using the six-minute walk test (6MWT), and quality of life with the Minnesota Living with Heart Failure Questionnaire (MLHFQ) both at baseline and after 6 months. Patients were stratified by etiology and analyzed according to SGLT2i use.Results: A total of 462 patients were included (275 non-ischemic, 187 ischemic); 86 (18.6%) received SGLT2i (45 non-ischemic, 41 ischemic). At 6 months, SGLT2i treatment significantly improved 6MWT in non-ischemic patients (+31.9 m, p = 0.005), but not in ischemic patients (+9.0 m, p = 0.411; P-interaction = 0.034). MLHFQ scores improved similarly in both groups, with no significant differences related to SGLT2i use.Conclusions: SGLT2i improved exercise capacity only in non-ischemic HFrEF patients, suggesting a differential response based on etiology.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2025-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144625678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of lipoprotein (a) elevation on coronary flow reserve. lıpoproteın (a) elevatıon对冠状动脉血流储备的影响。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-17 DOI: 10.1080/14779072.2025.2534707

Furkan Bolen, Adem Atici, Omer Faruk Baycan, Yusuf Yilmaz, İshak Yilmaz, Ayse Parali, Merve Kapcik, Oguz Konal, Nermin Ismayilzade, Fatma Betul Ozcan, Mustafa Caliskan

{"title":"The effect of lipoprotein (a) elevation on coronary flow reserve.","authors":"Furkan Bolen, Adem Atici, Omer Faruk Baycan, Yusuf Yilmaz, İshak Yilmaz, Ayse Parali, Merve Kapcik, Oguz Konal, Nermin Ismayilzade, Fatma Betul Ozcan, Mustafa Caliskan","doi":"10.1080/14779072.2025.2534707","DOIUrl":"10.1080/14779072.2025.2534707","url":null,"abstract":"Background: Lipoprotein (Lp)(a) is a genetically inherited lipoprotein implicated in the progression of cardiovascular diseases and atherosclerosis. This study aims to examine whether elevated Lp(a) levels contribute to the development of subclinical atherosclerosis, compared to individuals with normal Lp(a) levels, using parameters such as coronary flow reserve (CFR).Research design and methods: The study population included 25 patients with elevated Lp(a) levels and 30 subjects with normal Lp(a) levels, recruited prospectively. Conventional echocardiographic measurements were performed according to established guidelines. Main outcome measures included the comparison of CFR values between the groups.Results: The CFR was found to be significantly decreased in the group with elevated Lp(a) levels compared to the control group (2.0 ± 0.5 vs. 2.5 ± 0.6, p < 0.001). Additionally, a negative and statistically significant correlation was observed between Lp(a) levels and CFR, indicating that higher Lp(a) levels are associated with lower CFR values (r: -0.657, p < 0.001).Conclusions: Our study demonstrates that elevated Lp(a) levels are significantly associated with subclinical atherosclerosis and impaired coronary vasomotor function. These findings suggest that lowering Lp(a) levels could effectively reduce the risk of atherosclerotic disease by targeting its role in atherosclerosis pathogenesis.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144636635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Artificial intelligence for risk prediction in transcatheter heart valve interventions. 人工智能在经导管心脏瓣膜介入治疗中的风险预测。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-15 DOI: 10.1080/14779072.2025.2533241

Karim Jamhour-Chelh, Dabit Arzamendi, Lluis Asmarats

引用次数: 0

Clinical differences among types of in-stent calcifications in coronary arteries: how can this be better managed? 冠状动脉支架内钙化类型的临床差异：如何更好地处理？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-14 DOI: 10.1080/14779072.2025.2534715

Hiroyuki Jinnouchi, Kenichi Sakakura, Hideo Fujita

{"title":"Clinical differences among types of in-stent calcifications in coronary arteries: how can this be better managed?","authors":"Hiroyuki Jinnouchi, Kenichi Sakakura, Hideo Fujita","doi":"10.1080/14779072.2025.2534715","DOIUrl":"10.1080/14779072.2025.2534715","url":null,"abstract":"Introduction: In-stent calcification is recognized as a significant contributor to unfavorable clinical outcomes. Understanding the various types and underlying mechanisms of in-stent calcification can help interventional operators to make decisions.Areas covered: This review will describe the distinct types of in-stent calcification, which are categorized into in-stent smooth calcification and in-stent calcified nodule. The mechanisms and characteristics of in-stent smooth calcification and calcified nodule will be summarized. Given the differences between these two types, treatment approaches will be discussed. This review will focus on histopathology and intracoronary imaging. For the purpose of this review, evidence was gathered from electronic literature searches via PubMed, with a particular focus on primary evidence published in the last 5 years.Expert opinion: Several treatment devices are available such as conventional balloon, modified balloon, atherectomy device, and intravascular lithotripsy. In-stent smooth calcification and calcified nodule might result in different clinical courses after repeated target lesion revascularization. Understanding the mechanisms with the various types of in-stent calcification may assist operators in selecting appropriate treatment strategies.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144616931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex and race/ethnicity disparities on in-hospital outcomes in patients with severe aortic stenosis undergoing TAVR. 性别和种族/民族差异对严重主动脉瓣狭窄患者行TAVR的住院结果的影响

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-06 DOI: 10.1080/14779072.2025.2528916

Carlos Diaz-Arocutipa, Rafael Salguero, Elena Puerto, Roberto Martín-Asenjo, Lourdes Vicent

{"title":"Sex and race/ethnicity disparities on in-hospital outcomes in patients with severe aortic stenosis undergoing TAVR.","authors":"Carlos Diaz-Arocutipa, Rafael Salguero, Elena Puerto, Roberto Martín-Asenjo, Lourdes Vicent","doi":"10.1080/14779072.2025.2528916","DOIUrl":"https://doi.org/10.1080/14779072.2025.2528916","url":null,"abstract":"Background: We assessed the sex and racial/ethnic disparities on in-hospital outcomes in patients undergoing transcatheter aortic valve replacement (TAVR).Research design and methods: This retrospective study analyzed TAVR procedures performed during 2016-2019. Data from the National Inpatient Sample database identified 155,610 patients who underwent TAVR. Outcomes included in-hospital mortality, stroke, major bleeding, and other complications, assessed separately by sex and race/ethnicity (White, Black, and Hispanic). Logistic regression was used to estimate odds ratio (OR) with its 95% confidence interval (CI).Results: Women had higher odds of in-hospital mortality (OR 1.33, 95% CI 1.07-1.64), bleeding, and vascular complications, but lower odds of pacemaker implantation and renal replacement therapy compared with men. Hispanic patients had increased mortality (OR 1.86, 95% CI 1.26-2.75) and black patients had increased odds of stroke (OR 2.06, 95% CI 1.24-3.44). Subgroup analysis showed that Hispanic women had the highest mortality odds (OR 2.42, 95% CI 1.46-4.01).Conclusions: There are significant sex and racial/ethnic disparities in TAVR outcomes, particularly among minority women. Women had a higher odds of mortality, major bleeding, and vascular complications compared to men. Racial disparities were also seen, with Hispanic patients having an increased odds of mortality and black patients having an increased odds of stroke.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144575052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Routine invasive vs. conservative strategy in elderly patients with non-ST-elevation acute coronary syndrome. 老年非st段抬高急性冠状动脉综合征患者的常规侵入与保守治疗策略。

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-05 DOI: 10.1080/14779072.2025.2528922

Carlos Diaz-Arocutipa, Rafael Salguero, Roberto Martín-Asenjo, Elena Puerto, Juan Pablo Costabel, Adrian V Hernandez, Lourdes Vicent

{"title":"Routine invasive vs. conservative strategy in elderly patients with non-ST-elevation acute coronary syndrome.","authors":"Carlos Diaz-Arocutipa, Rafael Salguero, Roberto Martín-Asenjo, Elena Puerto, Juan Pablo Costabel, Adrian V Hernandez, Lourdes Vicent","doi":"10.1080/14779072.2025.2528922","DOIUrl":"10.1080/14779072.2025.2528922","url":null,"abstract":"Introduction: The optimal management of elderly patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) remains uncertain. This systematic review assessed routine invasive versus conservative strategies in this population.Methods: PubMed, Embase, and Scopus were searched through September 2024 for randomized controlled trials comparing both strategies. The primary outcome was major adverse cardiovascular events (MACE); secondary outcomes included all-cause mortality, cardiovascular mortality, non-cardiovascular mortality, myocardial infarction, revascularization, stroke, and bleeding. Evidence certainty was evaluated using GRADE, and meta-analyses applied random-effects models.Results: Seven RCTs (n = 2,997; mean age 81-86 years; 49% female) were included. Invasive strategy reduced MACE risk (HR 0.77, 95% CI 0.65-0.92), with consistent point estimate direction across trials. Myocardial infarction (HR 0.70, 95% CI 0.59-0.84) and revascularization (HR 0.45, 95% CI 0.23-0.90) were also significantly reduced. No significant differences were observed for all-cause mortality (HR1.04, 95% CI 0.90-1.19), cardiovascular mortality (HR 1.10, 95% CI 0.86-1.41), stroke (HR 0.78, 95% CI 0.53-1.16), or bleeding (RR1.23, 95% CI 0.90-1.69). Evidence certainty was moderate for most outcomes.Conclusions: In elderly NSTE-ACS patients, routine invasive strategy reduces cardiovascular events without significantly increasing bleeding, supporting individualized treatment decisions.Registration: The protocol for this study was registered in the PROSPERO repository (CRD42024600769).","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":1.8,"publicationDate":"2025-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144552777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluating the shared risk factors between atherosclerotic cardiovascular disease and cancer: how significant is the link? 评估动脉粥样硬化性心血管疾病和癌症之间的共同危险因素：这种联系有多重要？

IF 1.8

Expert Review of Cardiovascular Therapy Pub Date : 2025-07-01 DOI: 10.1080/14779072.2025.2527704

Brett Deng, Shubh Desai, Leslie Ynalvez, Moez Karim Aziz, Cezar Iliescu

{"title":"Evaluating the shared risk factors between atherosclerotic cardiovascular disease and cancer: how significant is the link?","authors":"Brett Deng, Shubh Desai, Leslie Ynalvez, Moez Karim Aziz, Cezar Iliescu","doi":"10.1080/14779072.2025.2527704","DOIUrl":"10.1080/14779072.2025.2527704","url":null,"abstract":"Introduction: Atherosclerotic cardiovascular disease (ASCVD) and cancer are the leading causes of death globally. While traditionally viewed as distinct, growing evidence reveals significant overlap in their risk factors and pathophysiology, suggesting a shared biological basis that warrants closer clinical and research attention.Areas covered: This review explores modifiable lifestyle and pathological risk factors that contribute to both ASCVD and cancer, including tobacco use, poor diet, physical inactivity, environmental toxins, hypertension, hyperlipidemia, obesity, insulin resistance, and sex hormone dysregulation. Mechanistically, these factors converge on common pathways such as chronic inflammation, oxidative stress, and hormonal imbalance, facilitating both atherogenesis and tumorigenesis. The paper also highlights how these shared mechanisms offer opportunities for unified prevention and treatment strategies.Expert opinion: Understanding these connections is critical for dual-risk stratification, prevention, and management strategies. Emerging approaches such as personalized medicine, leveraging genomic and biomarker data, and multidisciplinary care models that integrate cardiology and oncology expertise offer opportunities to optimize outcomes. Advances in multi-omics and targeted therapies promise to further elucidate the shared mechanisms, paving the way for innovative interventions. This comprehensive understanding highlights the need for integrated care to address the dual burden of ASCVD and cancer and improve patient outcomes.","PeriodicalId":12098,"journal":{"name":"Expert Review of Cardiovascular Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":1.8,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144527075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0